Prescribing overview
An equine NSAID for inflammatory musculoskeletal conditions. Symptom relief requires continued assessment of the underlying lameness.
Phenylbutazone reduces inflammation-related discomfort; it does not establish the cause of lameness. Reassess when response is poor, and review the complete medication list before repeat treatment. Inflammation associated with infection also requires appropriate anti-infective treatment.
Key prescribing checks
- Review the source-specific safety card and monitoring plan before use.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Horses
U.S. labeled/regulatory equine use; see exact scopeRelief of inflammatory conditions associated with the equine musculoskeletal system
Reviewed oral equine products; not a canine or feline prescribing regimen.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
A non-hormonal anti-inflammatory and antipyretic. Its apparent analgesic benefit is largely associated with reduced inflammation.
Absorption, distribution, metabolism and elimination
Equine pharmacokinetic literature describes a lipophilic acidic drug with extensive metabolism. No cross-formulation or cross-species dosing equivalence is established here.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Butequine / Pributazone
Selected U.S. equine oral phenylbutazone labels.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- The reviewed label places drug-allergy history under a caution statement; it is not presented here as an unconditional contraindication.
- Not for horses intended for human consumption. Pributazone labeling prohibits extra-label use in female dairy cattle aged 20 months or older.
This is a selected source summary, not exhaustive prescribing guidance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Gastrointestinal upset, black or tarry stool, jaundice and hematologic abnormalities require immediate reassessment.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Use the exact product label and veterinarian-selected shortest effective treatment plan. Numerical regimens and automatic calculations are not supplied.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Butequine / Pributazone
Selected U.S. equine oral phenylbutazone labels.
- Other NSAIDs or corticosteroids should be avoided or closely monitored according to the Pributazone label.
Monitoring
Follow the label-directed blood-count monitoring plan, particularly early in therapy, and assess appetite, stool and clinical response.
Client counseling
Stop and contact the veterinarian for label warning signs such as black stool or jaundice. Secure medication against accidental pet ingestion.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Paste and bolus storage ranges differ; follow the exact package and keep bolus containers tightly closed.
Brands, formulations & ingredient identity
Active ingredients
Phenylbutazone
Other searchable names: Bute · Butequine · Pributazone
Butequine paste and Pributazone boluses contain phenylbutazone but require their own product instructions.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Pributazone
- Formulation
- Phenylbutazone oral boluses
- Label / product scope
- Horses
References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
